Alp­na Seth

⇨ Long­time Bio­gen ex­ec Alp­na Seth has de­cid­ed to head west, way west, to re­join ex-Bio­gen CEO George Scan­gos as COO of his up­start biotech. He left the big com­pa­ny in Ju­ly, ac­cord­ing to the Boston Busi­ness Jour­nal.

⇨ With Ed­uar­do Sanchiz fol­low­ing through on step­ping down from the helm at Almi­rall, the com­pa­ny has re­cruit­ed a se­nior Sanofi ex­ec­u­tive for its new CEO. Pe­ter Guenter has spent the past 22 years at Sanofi, most re­cent­ly as ex­ec­u­tive vice pres­i­dent di­a­betes and car­dio­vas­cu­lar glob­al busi­ness unit.

⇨ PhRMA has brought in a top clin­i­cal re­search ex­pert — and se­nior FDA vet — to help guide its lob­by­ing work in Wash­ing­ton, DC. Richard Mosci­c­ki is jump­ing from his post as deputy di­rec­tor for sci­ence op­er­a­tions at CDER right over to a new role as chief med­ical of­fi­cer at PhRMA, which has been do­ing its best to spot­light the in­dus­try’s multi­bil­lion-dol­lar in­vest­ment in drug R&D as it seeks a help­ful stance from the fed­er­al gov­ern­ment on a score of key is­sues. Af­ter an in­ter­nal re­view that led the group to cut ties with com­pa­nies that had a less-than-stel­lar track record in in­vest­ing in R&D, Mosci­c­ki will bring an in­sid­er’s knowl­edge of the agency to his new role lead­ing sci­ence and reg­u­la­to­ry ad­vo­ca­cy ef­forts

Fred Cal­lori

⇨ Chris­t­ian Mey­er is the new chief med­ical of­fi­cer at Ther­a­chon. Mey­er’s re­sume in­cludes a stint as the CMO at uniQure where he had a help­ing hand in bring­ing the world’s most ex­pen­sive but no longer in pro­duc­tion drug Gly­bera to the mar­ket.

⇨ Cona­tus Phar­ma­ceu­ti­cals has bagged Kei­th Mar­shall for their EVP-COO-CFO com­bo gig.

⇨ Karolin­s­ka De­vel­op­ment’s lat­est CEO is Vik­tor Dr­vota, who re­placed Jim Van heus­den. Chair­man Bo Jes­per Hansen al­so de­cid­ed to step down and was re­placed by board mem­ber Niclas Adler.

⇨ Hu­mani­gen shares $HGEN were blitzed this week, right af­ter the com­pa­ny named Greg Jester as its new CFO.

⇨ Chris Garabe­di­an’s new com­pa­ny Xon­toge­ny has named Fred Cal­lori as SVP of cor­po­rate de­vel­op­ment. Cal­lori is a for­mer part­ner at Choate Hall & Stew­art with ex­pe­ri­ence cre­at­ing and fund­ing life sci­ences com­pa­nies.

Blue­bird bio $BLUE has un­veiled its price for the new­ly ap­proved gene ther­a­py Zyn­te­glo (Lenti­Glo­bin), which came as a big sur­prise. And it wasn’t the on­ly un­ex­pect­ed twist in to­day’s sto­ry.

With some an­a­lysts bet­ting on a $900,000 price for the β-tha­lassemia treat­ment in Eu­rope, where reg­u­la­tors pro­vid­ed a con­di­tion­al ear­ly OK, blue­bird CEO Nick Leschly said Fri­day morn­ing that the pa­tients who are suc­cess­ful­ly treat­ed with their drug over 5 years will be charged twice that — $1.8 mil­lion — on the con­ti­nent. That makes this drug the sec­ond most ex­pen­sive ther­a­py on the plan­et, just be­hind No­var­tis’ new­ly ap­proved Zol­gens­ma at $2.1 mil­lion, with an­a­lysts still wait­ing to see what kind of pre­mi­um can be had in the US.

Re­gen­eron’s close­ly-watched bis­pe­cif­ic con­tin­ues to ring up high re­sponse rates

Re­gen­eron’s high-pro­file bis­pe­cif­ic REGN1979 is back in the spot­light at the Eu­ro­pean Hema­tol­ogy As­so­ci­a­tion sci­en­tif­ic con­fab. And while the stel­lar num­bers we saw at ASH have erod­ed some­what as more blood can­cer pa­tients are eval­u­at­ed, the re­sponse rates for this CD3/CD20 drug re­main high.

A to­tal of 13 out of 14 fol­lic­u­lar lym­phomas re­spond­ed to the drug, a 93% ORR, down from 100% at the last read­out. In 10 out of 14, there was a com­plete re­sponse. In dif­fuse large B-cell lym­phoma the re­sponse rate was 57% among pa­tients treat­ed at the 80 mg to 160 mg dose range. They were all com­plete re­spons­es. And 2 of these Cars were for pa­tients who had failed CAR-T ther­a­py.

Em­bat­tled UK fund man­ag­er Neil Wood­ford — who has con­tro­ver­sial­ly blocked in­vestors from pulling out from his flag­ship fund to stem the blood­let­ting, af­ter a slew of dis­ap­point­ed in­vestors fled fol­low­ing a se­ries of sour bets — is now pay­ing the price for his ac­tions via an in­vestor ex­o­dus on an­oth­er fund.

Har­g­reaves Lans­down, which has in the past sold and pro­mot­ed the Wood­ford funds via its re­tail in­vest­ment plat­form, has re­port­ed­ly with­drawn £45 mil­lion — its en­tire po­si­tion — from the in­vest­ment man­ag­er’s In­come Fo­cus Fund.

→ Ab­b­Vie is tout­ing new pos­i­tive da­ta com­par­ing their ag­ing block­buster Hu­mi­ra with their hoped-for block­buster upadac­i­tinib. Over 48 weeks a larg­er pro­por­tion of pa­tients tak­ing the ex­per­i­men­tal drug ex­pe­ri­enced clin­i­cal re­mis­sion than in the con­trol arm with Hu­mi­ra. Their drug brought in $20 bil­lion last year, top­ping the scales in the num­ber 1 slot.

→ Gilead has turned to Van­cou­ver-based Ab­Cellera for its lat­est dis­cov­ery deal. Ab­Cellera will use its know-how in “sin­gle-cell screen­ing of nat­ur­al im­mune sources” to find an­ti­body can­di­dates for Gilead to pur­sue in the in­fec­tious dis­ease field. The deal in­cludes an up­front and mile­stones.

The Wash­ing­ton Post man­aged to whip up the quick­est in­dus­try con­sen­sus I’ve ever seen that one of its re­porters was pur­vey­ing overblown non­sense with a sto­ry that Pfiz­er was sit­ting on da­ta sug­gest­ing that En­brel could be an ef­fec­tive treat­ment for Alzheimer’s. 

In cov­er­ing that bit of an­ti-Big Phar­ma fan­ta­sy — there are lots of rea­sons to go af­ter phar­ma, but this piece was lu­di­crous — I not­ed com­ments in the sto­ry from some promi­nent peo­ple in the field crit­i­ciz­ing Pfiz­er for not pub­lish­ing the da­ta. I sin­gled out Rudy Tanzi at Har­vard and then ap­plied some added crit­i­cism for the things he’s done to hype — in my opin­ion — high­ly ques­tion­able as­sump­tions. You can see it in the link.